Zevra Therapeutics

Contributing Author

Recent Articles by Zevra Therapeutics

Jul-18	Zevra Therapeutics Announces MIPLYFFA and OLPRUVA Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG) ZVRA GlobeNewswire
Jul-16	Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism ZVRA GlobeNewswire
Jul-11	Zevra Therapeutics Announces MIPLYFFA (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference ZVRA GlobeNewswire
May-29	Zevra Announces Final Results of 2025 Annual Meeting of Stockholders ZVRA GlobeNewswire
May-21	All Three Leading Proxy Advisory Firms - ISS, Glass Lewis, and Egan-Jones - Recommend Zevra Stockholders Vote FOR the Company's Director Nominees ZVRA GlobeNewswire
May-13	Zevra Reports First Quarter 2025 Financial Results and Corporate Update ZVRA GlobeNewswire
May-06	Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call ZVRA GlobeNewswire
May-01	Zevra Therapeutics to Participate in the Citizens Life Science Conference ZVRA GlobeNewswire